T Cell Engaging Bispecific

Advertisement

cGxPJobs Banner

Context Therapeutics Doses First Patient in CT-202 Phase 1

PHILADELPHIA — September 9, 2026 Context Therapeutics Inc. announced that the first patient has been dosed in the Phase...

By cGxPwire Editor
September 10, 2026

Read More

Advertisement

cGxPJobs

Directory